Effect of argatroban on laboratory measurement of fibrinogen activity in ex vivo samples – Potential for errors in clinical decision‐making

International Journal of Laboratory HematologyEarly View LETTER TO THE EDITOR Effect of argatroban on laboratory measurement of fibrinogen activity in ex vivo samples – Potential for errors in clinical decision-making Sean Platton, Corresponding Author Sean Platton [email protected] orcid.org/0000-0002-5466-0448 Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London, UK Correspondence Sean Platton, Royal London Hospital, 4th Floor Pathology and Pharmacy Building, 80 Newark Street, London E1 2ES, UK. Email: [email protected]Search for more papers by this authorCharlotte Hill, Charlotte Hill Haemostasis Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorWill Lester, Will Lester Haemophilia Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorNada Yartey, Nada Yartey Department of Haematology, Barts Health NHS Trust, London, UK NHS East and South East London Pathology Partnership, Barts Health NHS Trust, London, UKSearch for more papers by this authorPeter MacCallum, Peter MacCallum Department of Haematology, Barts Health NHS Trust, London, UK Wolfson Institute of Population Health, Queen Mary University of London, London, UKSearch for more papers by this author Sean Platton, Corresponding Author Sean Platton [email protected] orcid.org/0000-0002-5466-0448 Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London, UK Correspondence Sean Platton, Royal London Hospital, 4th Floor Pathology and Pharmacy Building, 80 Newark Street, London E1 2ES, UK. Email: [email protected]Search for more papers by this authorCharlotte Hill, Charlotte Hill Haemostasis Laboratory, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorWill Lester, Will Lester Haemophilia Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKSearch for more papers by this authorNada Yartey, Nada Yartey Department of Haematology, Barts Health NHS Trust, London, UK NHS East and South East London Pathology Partnership, Barts Health NHS Trust, London, UKSearch for more papers by this authorPeter MacCallum, Peter MacCallum Department of Haematology, Barts Health NHS Trust, London, UK Wolfson Institute of Population Health, Queen Mary University of London, London, UKSearch for more papers by this author First published: 20 March 2023 https://doi.org/10.1111/ijlh.14061Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Watson H, Davidson S, Keeling D, Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. Br J Haematol. 2012; 159(5): 528- 540. doi:10.1111/bjh.12059 2Arachchillage DJ, Remmington C, Rosenberg A, et al. Anticoagulation with argatroban in patients with acute antithrombin deficiency in severe COVID-19. Br J Haematol. 2020; 190(5): e286- e288. doi:10.1111/bjh.16927 3 NICE. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis. 2021. July [cited 2023 Jan 27]. Available from https://www.nice.org.uk/guidance/ng200 4Kitchen S, Gray E, Mackie I, Baglin T, Makris M, BCSH Committee. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: guidance from the British Committee for Standards in Haematology. Br J Haematol. 2014; 166(6): 830- 841. doi:10.1111/bjh.12975 5Jennings I, Lester W, Gray E, et al. Effect of direct thrombin inhibitors on laboratory measurement of fibrinogen: potential for errors in clinical decision-making. Int J Lab Hematol. 2023. doi:10.1111/ijlh.14040. Online ahead of print. 6Zhang L, Yang J, Zheng X, Fan Q, Zhang Z. Influences of argatroban on five fibrinogen assays. Int J Lab Hematol. 2017 Dec; 39(6): 641- 644. doi:10.1111/ijlh.12719 7Siegmund R, Boer K, Poeschel K, Wolf G, Deufel T, Kiehntopf M. Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction. Blood Coagul Fibrinolysis. 2008; 19(4): 288- 293. doi:10.1097/MBC.0b013e3282fe73ec 8Molinaro RJ, Szlam F, Levy JH, Fantz CR, Tanaka KA. Low plasma fibrinogen levels with the Clauss method during anticoagulation with bivalirudin. Anesthesiology. 2008; 109(1): 160- 161. doi:10.1097/ALN.0b013e31817885b7 9Maier CL, Barker NA, Sniecinski RM. Falsely low fibrinogen levels in COVID-19 patients on direct thrombin inhibitors. Anesth Analg. 2020; 131(2): e117- e119. doi:10.1213/ANE.0000000000004949 10Baker P, Platton S, Gibson C, et al. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Br J Haematol. 2020; 191(3): 347- 362. doi:10.1111/bjh.16776 11 Westgard QC. Desirable biological variation database specifications. Madison, Wisconsin. 2019. [cited 2023 Jan 27]. Available from https://www.westgard.com/biodatabase1.htm 12Vu N, Jaynes E, Chan C, Dorsch M, Pipe S, Alaniz C. Argatroban monitoring: aPTT versus chromogenic assay. Am J Hematol. 2016; 91(6): E303- E304. doi:10.1002/ajh.24344 Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation